Abstract
transcripts have also been detected at high levels in the heart, kidney, and lung [7] [8] [9] [10] [11] and lower levels in other organs such as the testis and pituitary gland [3, 5, 6, 9, [12] [13] [14] . ACT, however, is a testis specific protein expressed in the spermatids of adult testis [6, 14] . In mouse, another FHL family member, FHL4, has been shown to be expressed exclusively in the testis, although not as abundantly for every LIM domain, contributing to the stabilization of the secondary and tertiary structure of the protein [3, 20] . [9] . Furthermore, LIM domains can also associate with tyrosine-containing motifs, PDZ domains, ankyrin repeats and helix-loop-helix domains [9] . Nonetheless, multiple efforts to identify conserved preferences for discrete binding sequences have not been successful [20] . [2, 20] . However, there is no evidence to date that LIM domains directly bind DNA [20, 22] . Furthermore, LIM domains have usually been observed to exert negative effects on the DNA binding of LIM homeodomain proteins [22] .
Considering its protein interaction properties, LIM domain containing scaffold proteins are capable of interacting with other LIM domain proteins, forming homo-or heterodimers

Multidimensional NMR spectroscopy and X-ray crystallography structural analysis studies have revealed a resemblance between the C-terminal zinc finger of LIM domains and the DNA-binding zinc finger of the GATA and steroid-hormone-receptor classes of transcription factors
The presence of a LIM domain was recently recognized as a potential hallmark of proteins associating with both the actin cytoskeleton and transcriptional machinery [20, 23] . For instance, the cysteine-rich proteins 1 and 2, each containing two LIM domains, interact with zyxin and alpha-actinin in the cytoplasm and participate in cytoskeletal remodelling [24, 25] . In addition, they translocate to the nucleus and act as bridging molecules interacting with both serum response factors and GATA proteins. In smooth muscle cells, this tetrameric complex activates gene targets and facilitates differentiation [26] . However, the physiological processes responsible for regulating the shuttling of LIM domain proteins between the cytoplasm and nucleus have not been elucidated [22] . [7, 10] . In addition, similar to FHL1, within the cell the isoform is distributed diffusely in the cytoplasm and nucleus, as determined from GFP-fusion protein expression from C2C12 myoblasts and HepG2 hepatocells [10] . Because FHL1C lacks any typical nuclear localization signal, its translocation to the nucleus may be mediated by particular protein modifications and/or protein interactions [10] . [10] . In the human heart, FHL1C transcript expression was more precisely localized in the left and right ventricles, with lower expression detected in the aorta and left atrium [10] . In contrast, murine KyoT2 exhibits a broader distribution, with transcripts expressed at higher levels in skeletal muscle, brain, lung, kidney and genital organs with lower detection from the thymus, lymph nodes and liver [7, 10] . The disparities in tissue distribution between [9] . However, it was originally referred to as SLIMMER for SLIM1 with extra regions [9] . The occurrence of a 200 bp insertion at position 741 results in the generation of three tandem putative bipartite nuclear localization signal motifs, followed by a nuclear export sequence and the identical putative RBP-J binding region found in FHL1C [8, 9] . Unlike FHL1C however, FHL1B is predominantly distributed in the nucleus of C2C12 myoblasts and HepG2 hepatocells, mainly attributable to the first bipartite nuclear localization signal [8, 9] . Interestingly, in differentiated myotubes, it is localized exclusively in the cytosol, similar to FHL1 [9] . Northern blot and RT-PCR tissue distribution analysis revealed greater abundance of FHL1B in skeletal muscle compared to heart, colon, prostate and small intestine. In addition to these tissues, murine KyoT3 mRNA was also detected in spleen, thymus, testis, ovary, brain, placenta, lung, liver, kidney and pancreatic tissue [8, 9] .
The presence of multiple LIM domains, each with a capacity for mediating protein interactions through diverse heterodimeric domain combinations, suggests considerable interaction possibilities for FHL1. In fact, 19 protein interactors have been identified thus far for full length FHL1 (Table 1). In addition, several additional 'putative' FHL1 interactions have been identified in largescale studies and have yet to be validated (Table 2) [27]. These FHL1 interactors can be mapped to a variety of different functional categories, including structural proteins, signal transducers, transcription regulators, receptors and a channel. Characterization of these interactions has so far provided much of the insight into the multi-functional roles of FHL1 and the majority of the interactions were identified from and/or validated in skeletal muscle or cancer cells. Thus, alterations in protein interactions, resulting from gene mutations and aberrant expression levels, could have significant implications in various disease conditions.
Spliced variants of FHL1
Notch signalling and KYOT2/3 proteins
The Notch signalling pathway is an evolutionarily conserved pathway participating in the control of a broad range of developmental processes, including cell fate determination, differentiation, proliferation and apoptosis through local cell-cell interaction [28] . Mammals [28, 29] . In the absence of transcriptional activators, RBP-J is capable of suppressing transcription of Notch target genes by binding several co-repressor proteins (Fig. 3) [28, 29] [28, 29] .
KyoT2 was discovered during yeast two hybrid screenings of mouse embryonic and HeLa cell cDNA libraries using RBP-J as the bait, and the interaction was subsequently verified in mammalian cell systems [7] . Because their binding regions on RBP-J overlap, KyoT2 competes with NIC for binding [7] . In contrast to NIC, KyoT2 interacts with RBP-J to suppress transcription, in a concentration-dependent manner [7, 29] . Furthermore, electrophoretic mobility shift assays revealed that whereas KyoT2 is capable of interacting with the RBP-J-DNA complex, it mostly displaces RBP-J from DNA, thus contributing to its repressional activities [7] . Subsequently, KyoT2 was found to interact with RING1 via its LIM domains [29] . RING1 belongs to the polycomb group proteins which function as transcription suppressors [29] . In co-transfected [29] . Similar patterns were also observed for HPC2, another polycomb group protein interactor of KyoT2 (Fig. 3) [7, 29, 30] . [11] . However, RT-PCR analysis of Hes-1 mRNA levels revealed KyoT3-mediated repression occurred only in the presence of NIC. In the absence of NIC, elevated Hes-1 mRNA was detected in the presence of KyoT3 [11] . It is plausible KyoT3 recruits other molecules to any of its LIM domains to transactivate the Hes-1 promoter or antagonize the repression of RBP-J activity [11] .
HEK-293 and COS7 cells, RING1 was shown to form a multimeric complex with KyoT2 and RBP-J, contributing to the repression of RBP-J mediated transactivation. These effects could be abrogated by human immunodeficiency virus type I enhancer binding protein 3, which competes with RING1 to bind KyoT2 at both LIM domains
Similar to KyoT2, KyoT3 was recently demonstrated to compete with NIC for binding RBP-J and repressing transactivation of RBP-J dependent promoters
KyoT2 repression of Notch signalling in cells via interaction with RBP-J can be modulated by PIAS1, promoting transactivation of RBP-J [31]. Considering KyoT2 interacts with two small ubiquitinrelated modifier (SUMO) modification E3 ligases (HPC2 and PIAS1),
KyoT2 was suggested to be a substrate for SUMOylation [30, 31] . This was verified when the effects of PIAS1 were neutralized in the presence of Sentrin/SUMO-specific protease SENP2, a SUMO hydrolase [31] . PIAS1 promotes SUMOylation of KyoT2 at two sites, K144 in the second LIM domain, and K171 near the RBP-J binding motif, which antagonizes KyoT2's repressor activity (Fig. 3) . In particular, modification of the K171 site most counteracted the repression. Unlike PIAS1, overexpression of HPC2 did not enhance SUMOylation of KyoT2 beyond basal levels [31] . In general, SUMOylation can alter the stability, localization and biological activities of modified proteins [31] . In the case of KyoT2, no effects on its subcellular localization or interaction with RBP-J were detected [31] .
Expression patterns of FHL1
Northern blot analyses of a panel of tissue samples obtained from human, rat and sheep subjects identified expression of FHL1 in
skeletal muscle across multiple species [1, 5] [32] .
. In mature skeletal muscle, FHL1 is localized at the I-band, encompassing the Z-line, and transiently at the M-line where it extends partially into the C-zone of the A-band. The resulting transverse banding pattern is of alternating thick and thin bands, corresponding to the I-band and the centre of the A-band, respectively
In embryonic mouse skeletal muscle FHL1 was first detected at E8.75 in the heart and neural tube via in situ hybridisation, using whole mount mouse embryos. At E9.5, FHL1 was prominent in the hindbrain and neural tube, with conspicuous expression in the cardiac outflow tract although the endothelium was not the source of expression in the outflow tract [33] . At E11, however, FHL1 was detected in the somites with a pattern corresponding to the [89] developing myotomes, in addition to a continued expression in the outflow tract and neural tube [33] . Generally consistent with these earlier studies, using whole mount X-gal staining of FHL1 reporter transgenic mouse embryos, a broader FHL1 mRNA distribution has been observed [34] . At E10.5, the heart, somites, limb buds, neural tube, brain and eye stained positive for FHL mRNA. At E14, FHL1 was strongly expressed in the neural tube, and the aorta and pulmonary trunk of the vasculature, and less prominently in the myocardium [34] . Furthermore, strong X-gal staining was also observed in the tongue, limb buds, abdominal muscle, intercostal muscle and thoracic muscle [33, 34] .
Enriched FHL1 transcript expression was also detected by in situ hybridization in slow twitch soleus muscle in adult rat, when compared to the fast-twitch gastrocnemius muscle. The specificity of FHL1 expression correlated better with the oxidative properties of muscle fibres rather than the fibre types. Soleus muscle is composed of the highly oxidative type I and type IIa fibres, whereas gastrocnemius is largely composed of the glycolytic type
IIb fibres [35] .
In the murine C2C12 skeletal muscle cell line, FHL1 expression was detected in myoblasts before the onset of differentiation [5, 36] . During the first 24-48 hrs of differentiation, however, FHL1 expression initially declined by 40% before resuming its inclined expression pattern up to about 6 days [5, 36] . Furthermore, the expression profile of FHL1 was similar to those of the myogenic regulatory factors, myogenin and MRF, and to the growth factor IGF-II. However, FHL1 was present before the onset of myogenin and muscle specific embryonic, neonatal and adult 2b MyHCs expression [5] . [40] . Immunoblot and immunostaining analysis revealed almost complete absence of FHL1A protein in both fibres from affected individuals [39, 40] . Granulofilamentous material was observed via electron microscopy, and staining identified the presence of a few cytoplasmimc bodies, although there was no evidence of reducing bodies [40] . Such histopathology suggests XMPMA may share pathophysiological pathways with myofibrillary myopathies [40] .
FHL1 and disease FHL1 and skeletal muscle myopathies
To date however, the greatest number of FHL1 gene mutations have been associated with X-linked reducing body myopathy (XRBM), with all 11 known amino acid substitution mutations and one deletion mutation occurring in the second LIM domain [41] [42] [43] . Clinically, XRBM is a rare muscular disorder causing progressive muscular weakness, generally affecting proximal [47] [48] [49] [50] . [51] . In
Furthermore, alterations in LIM domains and protein conformation affect the binding interfaces for protein interactions. In XMPMA, insertion of a single isoleucine residue between two amino acids connecting adjacent zinc fingers of the second LIM domain, thereby nonconforming with the consensus C-X2-C spacing, was expected to adversely affect proteins interactions (the protein's interaction or protein interactions?) [39]. The first two LIM domains, for instance, were deemed essential for mediating interactions with RAF1, MEK2 and ERK2 in cardiac muscle
C2C12 skeletal muscle cells co-expressing myc-NFATc1 with either HA-FHL1
C132F or HA-FHL1
H123Y
, immunoprecipitation of myc-NFATc1 revealed an ~80% reduction in interaction with mutant FHL1 [52] . FHL1 positive aggregates in XRBM were also found to sequester FHL1 interacting proteins MyBP-C and NFATc1, possibly contributing to the reduced interaction observed in C2C12 cells [41, 52] .
FHL1 expression levels in cardiovascular diseases
Differential FHL1 expression has previously been associated with several cardiovascular diseases. In our group, a transgenic mouse model was generated to recapitulate early onset dilated cardiomyopathy observed in humans and caused by an Arg-9-Cys conversion in phospholamban, an integral membrane phosphoprotein of the sarcoplasmic reticulum [53, 54] . [54] . Similarly, FHL1 was also detected to be up-regulated during comparative gene expression profiling of transgenic mice overexpressing Gs-alpha, with respect to control littermates [55] . Similar [56] . In diseased hearts, FHL1 was found to be down-regulated at both the mRNA and protein level [56] . Thus [57] [58] [59] . Thus, continued study of FHL1 with respect to heart failure is warranted, especially because hypertrophic and dilated cardiomyopathy do share common pathways in disease development [60] .
From a large-scale comparative proteomic profiling of ventricular muscle tissue, FHL1 was identified among a subset of 40 top ranked differentially expressed proteins as one of the four most up-regulated, with changes occurring early in disease
Low-density cDNA array analysis of atrial fibrillation induced by rapid atrial pacing in porcine identified FHL1 transcripts to be significantly up-regulated (3.17 fold), which translated to a 2.9-fold increase at the protein level [61] . Its elevated expression occurred in both the right and left atria at similar levels [61] . A capacity for influencing electrophysiology was demonstrated for FHL1, as described later [62] . Furthermore, although FHL1 was abundant and present at muscle striations, immunostaining revealed a more disorganized and diffuse cytoplasmic staining with slight nuclear localization in the fibrillating atria [61] . [61] . The rapid response may have been mediated via activation of the ␤-AR signal transduction pathway, a relationship that was already implicated above [55, 61] . Isoproterenol is a ␤-adrenergic agonist and ␤2-AR was also up-regulated in atrial fibrillation [61] . An involvement of the adrenergic signalling pathway in atrial remodelling during atrial fibrillation has been postulated [61, 63] . Altogether, these results are consistent with the observation that atrial fibrillation was common among patients of FHL1 mutation-induced myopathies.
Translocation to the nucleus could possibly invoke a transcriptional regulation function for FHL1 in differentiated cardiac cells during arrhythmia. Furthermore, in cultured cardiomyocytes treated with the proarrhythmogenic substrate isoproteronol, FHL1 expression was up-regulated 3.1-fold
Elevated FHL1 expression has also been detected in pulmonary hypertension [64] . Proteomic analysis initially identified FHL1 to be up-regulated in lung tissues of a mouse model of hypoxiainduced pulmonary hypertension, and also verified in two rat models. More importantly, the pattern was mirrored in idiopathic pulmonary arterial hypertension human patient samples, and interestingly FHL2 and FHL3 levels were not altered [64] . Furthermore, in mice subjected to prolonged hypoxia a time dependent increase in FHL1 expression was observed [64] . Its expression was revealed to be strongest in vascular smooth muscle cells, with positive staining also present in neomuscularized resistance vessels. However, the hypoxia-dependent up-regulation of FHL1 was restricted to the pulmonary vasculature, whereas time-dependent reduction in FHL1 occurred in the systemic vasculature [64] . It appears the hypoxia-driven expression of FHL1 was controlled by hypoxia-inducible transcription factors 1 and 2, two major gene regulators active during low oxygen tension. In the absence of either transcription factor, FHL1 levels were significantly lower in hypoxic conditions. In addition, several putative hypoxia-inducible transcription factor-binding sites were detected in the FHL1 gene promoter region, with binding activity by hypoxia-inducible transcription factor proteins occurring only under hypoxia [64] . [65] . In myoblasts plated on poly-L-lysine, however, FHL1 was diffusely localized in the cytosol with decreased nuclear expression. Cytochalasin D and nocodazole treatments, respectively, eliminated an intact actin cytoskeleton and microtubules as necessary for the nuclear localization of FHL1 in integrin-activated myoblasts [65] .
FHL1 and muscle-associated functions
overexpression of GFP-FHL1 in myoblasts plated on fibronectin inhibited myoblast adhesion and enhanced cell spreading and migration, mediated specifically by ␣5␤1-integrin [65]. The use of a modified Transwell migration assay, coated with fibronectin, demonstrated the proportion of GFP-FHL1 expressing myoblasts in the migrating population was twofold greater than in the non-migrating cells. In contrast, migration ceased to occur in the presence of poly-L-lysine, a non-specific inhibitor of integrin activation. In addition, in integrin-activated myoblasts dual localization of FHL1 was observed in the nucleus and the cytoplasm, specifically at focal adhesions and along stress fibres
Similarly, ectopic expression of FHL1 in Sol8 or C2C12 myoblasts, plated on fibronectin and subjected to differentiation conditions, induced two distinct phenotypes, either hyper-elongated or highly branched [36] . Hyper [36] .
A role for FHL1 has also emerged in pulmonary vascular remodelling following evidence for involvement in the migration and proliferation of primary human pulmonary artery smooth muscle cells (PASMC) [64] . SiRNA mediated silencing of FHL1 significantly decreased human and murine PASMC migration and proliferation activities, whereas overexpresison enhanced these activities [64] . Parallel [64] . Integrin-mediated cell adhesion has also been shown to regulate cyclinD1 protein levels [64] .
Characterization of the FHL1 interaction with MyBP-C revealed a role in myosin filament formation and sarcomere assembly [32] [51] . A specific role for FHL1 in diastolic tension was also suggested when muscle displayed reduced diastolic stress and increased compliance [51] . The N2B element of titin is a component of the extensible region of titin, which contributes to the myofibrillar passive tension generated upon stretch [51] .
Furthermore [51] . The Gq signalling pathway has previously been shown to regulate ERK activation in pressure overload conditions [66] .
Overexpression [78] . In addition, the expression of FHL1 positively correlated with the expression of epidermal growth factor 2, a prognostic biomarker in breast cancer [78] . In primary gastric cancer patients, a significantly shorter survival was observed from patients with lower FHL1 expression levels [71] . Furthermore, FHL1 suppression appeared greatest in widely invasive and metastatic cases [69] [70] [71] 79] . Analogous to these findings, FHL1 was identified as a tumour suppressor gene, which acts to inhibit non-anchored cell growth and migration, downstream of Src-and Crk-associated substrate (Cas) signalling (Fig. 4A) [70] . In Src-transformed cells however, the membrane bound Src tyrosine kinase phosphorylated Cas, a focal adhesion adaptor protein, to suppress FHL1 expression and promote anchorage independence and motility, hallmarks of tumour cell growth [70] . The potential for MAPK, a kinase activated by Src, involvement in FHL1 suppression was eliminated when transformed cells incubated with an MEK blocker failed to express FHL1 [80] . In FHL1 overexpressing cells, colonization was inhibited, whereas non-anchored growth and migration was enhanced [70] . In addition, FHL1 production was induced almost twofold in Src-transformed cells following contact by adjacent non-transformed cells [70, 81] [70, 81] . Furthermore, FHL1 gene silencing was induced by hyper-methylation of its promoter region, a CpG rich region [80] . Thus, diminished FHL1 expression likely attributes to poorer survival via heightened biological aggressiveness of the tumour [71] . [77] .
Similarly, transfection of FHL1 in breast cancer cells also inhibited cell growth, both anchorage-dependent and -independent. Conversely, siRNA mediated silencing of FHL1 significantly increased cell growth, and 17␤-estradiol exposure only amplified these effects [78] . These results could be mediated by the interaction between FHL1 and estrogen receptors ␣ or ␤ in breast cancer cells, which occurs independent of 17␤-estradiol (Fig. 4C) [78] . FHL1 acts as a negative regulator of estrogen receptor mediated transcription, subsequently repressing expression of estrogenresponsive genes, such as pS2 and cathepsin D [78] . In human breast cancer SKBR3 cells, which lack endogenous estrogen receptor ␣, FHL1 failed to inhibit target protein expression [78] . Thus, FHL1 acts through the estrogen receptors to repress transcription. Furthermore, FHL1 likely mediates its co-repressor effects by inhibiting the binding of estrogen receptor ␣ to estrogen responsive elements present in the promoter of estrogen responsive genes [78] . Abrogation of FHL1 expression enhanced estrogen signalling, as evidenced from estrogen responsive element driven luciferase assays [82] . When FHL1 is co-expressed with receptor interacting protein of 140 kDa, a cofactor also capable of inhibiting estrogen receptor ␣, a synergistic inhibition of estrogen-responsive target gene transcription occurs [82] .
In contrast to the suppression of FHL1 in many cancers and the phenotype rescue by ectopic FHL1 expression in tumour cells, FHL1 is aberrantly expressed in most T cell acute lymphoblastic leukaemia cell lines, particularly those exhibiting deregulated TLX1/HOX11 expression [83] . TLX1/HOX11 is a homeodomain protein whose abnormal expression, induced by translocations affecting chromosome 10q24, contributes to the leukaemogenesis of T cell tumours [83, 84] . In murine NIH3T3 fibroblasts, expression of TLX1/HOX11 resulted in abnormal growth patterns in vitro and formed tumours in athymic nude mice [84] . Ectopic expression also transcriptionally activated FHL1, functioning as a concentration-dependent regulator [83, 85] . The need for high TLX1/HOX11 levels to stimulate FHL1 expression could explain the lack of consistent FHL1 expression in TLX1/HOX11 positive samples [85] . Regulation of FHL1 expression also required an intact N-terminal transactivation domain and DNA binding capabilities, and was mediated through specific elements located in its proximal promoter [85] . Thus 
